Arthur Allen

Visit kff.org to read Arthur's bio.

aallen@kff.org
@ArthurAllen202

Una FTC más agresiva persigue las fusiones en la industria farmacéutica y a los intermediarios del sector

KFF Health News Original

La Comisión Federal de Comercio está actuando contra las empresas farmacéuticas y los intermediarios del sector, como parte de la campaña de la administración Biden para reducir los precios de los medicamentos en las farmacias.

The Drug Company That Prospered Without Creating Any Drugs

KFF Health News Original

Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair

KFF Health News Original

The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.

¿Por qué cuesta tanto la insulina? Las grandes farmacéuticas no son las únicas que influyen en los precios

KFF Health News Original

La insulina representa lo perverso del sistema sanitario estadounidense, ya que los precios de venta de este medicamento centenario, del que dependen 8,4 millones de estadounidenses para sobrevivir, se quintuplicaron en dos décadas.

‘We Ain’t Gonna Get It’: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait

KFF Health News Original

As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.

A Technicality Could Keep RSV Shots From Kids in Need

KFF Health News Original

The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine.

FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When

KFF Health News Original

A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.

Is Legislation to Safeguard Americans Against Superbugs a Boondoggle or Breakthrough?

KFF Health News Original

While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.

Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas

KFF Health News Original

While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

$38,398 for a Single Shot of a Very Old Cancer Drug

KFF Health News Original

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?

Big Pharma Went All In to Kill Drug Pricing Negotiations

KFF Health News Original

For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.

Qué significa el caso de Nueva York para el fin de la polio

KFF Health News Original

Para 2015, la polio se había erradicado casi por completo en todas partes excepto en Pakistán y Afganistán. Pero para 2020 se habían reportado casos en 34 países.

¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid

KFF Health News Original

Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.